Patients’ demographic characteristics and CSF parameter in the diagnostic groups
| n | m/f | Age | NfL (pg/mL) | pNfH (pg/mL) | Tau (pg/mL) | pTau (pg/mL) | Qalb | Total protein (µg/mL) | |
|---|---|---|---|---|---|---|---|---|---|
| MND | 253 | 160/93 | 62 19–85 | 5068 100–38 350 | 1911 62–19 160 | 246 64–1096 | 44 15–129 | 6.3 2,6–23.5 | 499 148–1920 |
| ALS | 222 | 141/81 | 63 30–85 | 4990 100–38 350 | 1825 62–19 160 | 245 71–1096 | 44 15–129 | 6.3 2.6–23.5 | 501 148–1410 |
| PLS | 11 | 5/6 | 56 40–75 | 3750 100–25 650 | 1340 62–8940 | 247 149–661 | 46 23–57 | 6.3 2.7–16.3 | 493 223–1120 |
| fALS | 20 | 14/6 | 56 19–79 | 6452 785–22 040 | 3490 455–1326 | 262 64–735 | 49 19–129 | 6.6 2.8–23.0 | 489 254–1920 |
| MND mimics | 85 | 66/19 | 57 21–86 | 865 168–10 000 | 274 62–10 000 | 224 82–600 | 46 15–100 | 6.3 2.7–50.0 | 521 205–2750 |
| AD | 28 | 11/17 | 69 57–87 | 1510 625–9507 | 276 169–689 | 606 228–1520 | 73 36–181 | 5.7 3.6–11.0 | 646 284–866 |
| PS | 26 | 19/7 | 73 42–83 | 1455 439–4841 | 499 79–1228 | 276 161–627 | 37 24–112 | 6.5 2.7–12.0 | 477 104–807 |
| PNP | 33 | 20/13 | 69 21–83 | 1034 277–24 330 | 385 86–37 620 | 243 52–745 | 37 18–92 | 6.9 2.7–19.1 | 543 225–1260 |
| Facial palsy | 30 | 20/10 | 43 18–86 | 585 100–2676 | 237 62–919 | 204 77–527 | 37 21–72 | 5.8 2.8–16.4 | 463 226–1140 |
Given are the median values and ranges.
AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; CSF, cerebrospinal fluid; f, female; fALS, familial ALS; m, male; MND, motoneurons disease; NfL, neurofilament light chain; PLS, primary lateral sclerosis; pNfH, phosphorylated heavy chain; PNP, polyneuropathy; PS, Parkinson's syndrome; pTau, phospho-tau protein; Qalb, CSF/serum albumin ratio; Tau, tau protein.